Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lonza GroupXSWX:LONN +0.99%85 Debt-to-Equity is 0.51 as of Jun. 2026, which is 6% below its 10-year median of 0.54. GuruFocus rates XSWX:LONN with a GF Score™ of 85/100 and a GF Value™ of CHF580.03 (Fairly Valued). The stock has 4 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Lonza Group ranks worse than 64.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lonza Group's Debt-to-Equity or its related term are showing as below:
XSWX:LONN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.54 Max: 0.81
Current: 0.51
During the past 13 years, the highest Debt-to-Equity Ratio of Lonza Group was 0.81. The lowest was 0.24. And the median was 0.54.
XSWX:LONN's Debt-to-Equity is ranked worse than 64.48% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.31
vs XSWX:LONN: 0.51
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lonza Group Debt-to-Equity Related Terms
Lonza Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lonza Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LONN vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Lonza Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lonza Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (XSWX:LONN) has a Debt-to-Equity of 0.51 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lonza Group and its competitors. This is near median its historical median of 0.54. Over the past decade, Lonza Group's Debt-to-Equity has ranged from 0.24 to 0.81. According to the industry distribution chart, Lonza Group ranks #118 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 64.5%.
Is Lonza Group's Debt-to-Equity too high?
Lonza Group's current Debt-to-Equity of 0.51 is near median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.81. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. Lonza Group's value of 0.51 is 64.5% above this industry median. Based on the distribution chart, Lonza Group ranks #118 out of 183 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lonza Group has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #118 out of 183 companies for Debt-to-Equity. This places Lonza Group in the lower half of its industry. The industry median Debt-to-Equity is 0.31. Lonza Group's value of 0.51 is 64.5% above this benchmark. Historically, Lonza Group's own Debt-to-Equity has ranged from 0.24 to 0.81 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 0.31, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current Debt-to-Equity of 0.51 is 64.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current Debt-to-Equity is 0.51, which is near median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Fairly Valued. The stock's GF Value™ is CHF580.03, compared to a current price of CHF572.20 — trading 1.3% below its estimated fair value. The current Debt-to-Equity is 0.51, which is near median its 10-year median of 0.54 and 64.5% above the Medical Diagnostics & Research industry median of 0.31. Lonza Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current Debt-to-Equity is 0.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of CHF572.20 is trading 1.3% below its estimated GF Value™ of CHF580.03.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for XSWX:LONN:
Debt-to-Equity: 0.51 (near median its 10-year median of 0.54)
GF Value™: CHF580.03 vs. price of CHF572.20 (1.3% below fair value)
Industry Position: 64.5% above the Medical Diagnostics & Research median (#118 of 183)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
85GF Score
Get the complete analysis for XSWX:LONN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
